4.1 Review

Treatment of Pediatric Obsessive-Compulsive Disorder: A Review

期刊

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/cap.2010.0040

关键词

-

资金

  1. Boehringer Ingelheim
  2. Otsuka
  3. Eli Lilly
  4. Pediatric Obsessive-compulsive and Related Disorders fund
  5. Eli Lilly and Co.
  6. Forest Laboratories
  7. Glaxo-SmithKline
  8. Pfizer
  9. Ethel DuPont Warren Fellowship
  10. American Academy of Child and Adolescent Psychiatry [2005]
  11. National Institute of Mental Health
  12. McNeil Pediatrics
  13. SynerMed Communications
  14. Bristol Myers Squibb
  15. Glaxo Smith Kline
  16. Shire
  17. Johnson Johnson
  18. Merck
  19. Cephlon
  20. McNeil
  21. Eli-Lily
  22. Abbott
  23. Novartis
  24. Organon
  25. Takeda
  26. New River Pharmaceuticals

向作者/读者索取更多资源

Recently, research in pediatric obsessive-compulsive disorder (OCD) has expanded to include large family genetic studies, elaboration of phenotypic dimensions, description of co-morbid disorders and their moderating effects on treatment response and outcome, research on immune-based neuropsychiatric causes, randomized controlled trials of selective serotonin re-uptake inhibitors (SSRIs), randomized controlled trials of cognitive behavioral therapy (CBT), comparative treatment trials; new approaches in behavior therapy, and increased awareness of newer approaches to treatment. The purpose of this article is to review assessment and treatment strategies to include current advances in research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据